NCT03917381: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

NCT03917381
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only TNBC patients will be eligible for part 2 (expansion phase)
Exclusions: 
https://ClinicalTrials.gov/show/NCT03917381

Comments are closed.

Up ↑